Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK2 | P51955 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL357968 | 0.91 | — | — | |
| SCHEMBL10079077 | 0.81 | — | — | |
| SCHEMBL15916793 | 0.78 | TSHR (0.37) | NEK2 | |
| SCHEMBL14164399 | 0.75 | CYP1A2 (0.38) | — | |
| SCHEMBL25326513 | 0.74 | — | — | |
| SCHEMBL90095 | 0.74 | — | — | |
| SCHEMBL15915008 | 0.74 | SCN1A (0.33) | — | |
| SCHEMBL29876969 | 0.74 | — | — | |
| SCHEMBL14571194 | 0.72 | NPSR1 (0.31) | — | |
| SCHEMBL1107068 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118103352-A | Spiroindoline inhibitors of KIF18A | 沃拉斯查疗法公司 | 2024-05-28 | — | — | CN | disclosed |
| US-11174268-B2 | Benzenesulfonamide compouds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2021-11-16 | — | — | US | disclosed |
| US-20210171537-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2021-06-10 | — | — | US | disclosed |
| EP-3551626-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2019-10-16 | — | — | EP | disclosed |
| US-10005739-B2 | Quinazolinone and isoquinolinone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2018-06-26 | — | — | US | disclosed |
| US-20180162868-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2018-06-14 | — | — | US | disclosed |
| WO-2018106284-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2018-06-14 | — | — | WO | disclosed |
| EP-2953681-B1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INT (DE) | 2017-03-15 | — | — | EP | disclosed |
| US-20160272595-A1 | QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-09-22 | — | — | US | disclosed |
| EP-3061749-A1 | QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2016-08-31 | — | — | EP | disclosed |
| EP-2953681-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | Boehringer Ingelheim International GmbH (DE) | 2015-12-16 | — | — | EP | disclosed |
| US-8927531-B2 | Indanyloxydihydrobenzofuranylacetic acids | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| WO-2014122067-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-14 | — | — | WO | disclosed |
| US-20140221349-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272595-A1 | QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE | NQO2, SDHA, CYP3A5 | NEK2 725/4885 |
| US-10005739-B2 | Quinazolinone and isoquinolinone derivative | NQO2, SDHA, CYP3A5 | NEK2 725/4885 |
| US-11174268-B2 | Benzenesulfonamide compouds and their use as therapeutic agents | KCND2, SCN1A, CACNA1D | NEK2 980/4885 |
| US-20210171537-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN1B, SCN2B | NEK2 1252/4885 |
| US-20140221349-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | GPR119, GPBAR1, GPR52 | NEK2 4359/4885 |
| US-20180162868-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN1B, SCN2B | NEK2 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.